Medication, Women's Health
Beyond Estrogen: Exploring Innovative Therapy for GSM in Menopausal Women
DURATION
30 min
PROFESSION
Physician
# OF CREDITS
0.5
ACCREDITATION
Mainpro+
EXPIRY DATE
2025-11-05
Genitourinary syndrome of menopause (GSM) encompasses a range of symptoms resulting from sex steroid deficiency, affecting the vagina, vulva, and lower urinary tract (ie. bladder and urethra). Vulvovaginal symptoms of GSM are characterized by thinning of the vulvar and vaginal tissues, resulting in dryness, irritation, bleeding, itch, and pain. Despite its prevalence, GSM remains underdiagnosed and undertreated, particularly in primary care settings. Recent advancements have introduced new ways of treating hormone deficiency using therapies that incorporate both estrogen and androgen, and oral therapies. This expert brief explores the evolution of targeted prescription treatment options, with a special focus on the two newly Health Canada-approved effective therapies for GSM: prasterone, an inactive precursor of sex steroids that enters the vaginal cells and is converted intracellularly into estrogens and androgens, and ospemifene, a selective estrogen receptor modulator (SERM). Through patient case discussions, this expert brief aims to provide healthcare providers with practical guidance on selecting appropriate candidates for these newer targeted prescription GSM therapies, educating patients on treatment benefits and risks, and integrating these therapies into primary care.
Faculty
Michelle Jacobson, MD, FRCSC
Shafeena Premji, MHA, MD, CCFP, FCFP, MSCP
Naomi Pliamm, MD, CCFP
Phuongbich Nguyen, MD, MCFP
Learning objectives
After viewing this expert brief, participants will be better able to:- Identify signs and symptoms of genitourinary syndrome of menopause (GSM)
- Describe newly Health Canada-approved targeted prescription treatments for GSM
- Treat root causes of GSM
- Implement best practices for management of GSM in primary care
Accreditation
This self-learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.
Cert+ Program ID#: 203498
#
of credits: 0.5
Duration: 30 min
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
30 min
Duration
Physician
Profession
0.5
# of credits
Learning Objectives
After viewing this expert brief, participants will be better able to:
- Identify signs and symptoms of genitourinary syndrome of menopause (GSM)
- Describe newly Health Canada-approved targeted prescription treatments for GSM
- Treat root causes of GSM
- Implement best practices for management of GSM in primary care
Mainpro+
ACCREDITATION
Medication, Women's Health
Learning Category
Medication, Menopause, Women's Health
Topic
0
Price
2025-11-05
Expiry Date
CAN-eng
Region/Language
Course Description
Genitourinary syndrome of menopause (GSM) encompasses a range of symptoms resulting from sex steroid deficiency, affecting the vagina, vulva, and lower urinary tract (ie. bladder and urethra). Vulvovaginal symptoms of GSM are characterized by thinning of the vulvar and vaginal tissues, resulting in dryness, irritation, bleeding, itch, and pain. Despite its prevalence, GSM remains underdiagnosed and undertreated, particularly in primary care settings. Recent advancements have introduced new ways of treating hormone deficiency using therapies that incorporate both estrogen and androgen, and oral therapies. This expert brief explores the evolution of targeted prescription treatment options, with a special focus on the two newly Health Canada-approved effective therapies for GSM: prasterone, an inactive precursor of sex steroids that enters the vaginal cells and is converted intracellularly into estrogens and androgens, and ospemifene, a selective estrogen receptor modulator (SERM). Through patient case discussions, this expert brief aims to provide healthcare providers with practical guidance on selecting appropriate candidates for these newer targeted prescription GSM therapies, educating patients on treatment benefits and risks, and integrating these therapies into primary care.
Faculty
Michelle Jacobson, MD, FRCSC
Shafeena Premji, MHA, MD, CCFP, FCFP, MSCP
Naomi Pliamm, MD, CCFP
Phuongbich Nguyen, MD, MCFP
Accreditation
This self-learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.
Cert+ Program ID#: 203498
30 min
Duration
0
Price
0.5
# of credits
